Skip to main content

Treace Announces Grant of U.S. Patent and Allowance of U.S. Patent Application on Bone Positioner Technology for Bunion Correction

Written by Customer Service on . Posted in Public Companies.

PONTE VEDRA, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announced today that the United States Patent and Trademark Office granted to the Company U.S. Patent No. 11,185,359, titled “Bone Positioning Guide,” and also issued a Notice of Allowance for the Company’s pending U.S. Patent Application No. 17/353,431, titled “Bone Positioning and Preparing Guide Systems and Methods.”  

The granted patent relates generally to techniques, including for use in bunion correction surgery, for moving the first metatarsal with a positioning instrument. The allowed patent application relates generally to techniques for correcting a bunion deformity involving the use of a bone preparation guide and a positioning instrument. The newly granted patent and allowed patent application expand Treace’s comprehensive patent coverage on instrumented bunion correction techniques with particular emphasis on metatarsal bone positioning instrumentation, a product category Treace pioneered through its innovative development efforts.

“We are pleased that the Patent Office continues to recognize the novel advances made by Treace Medical. The addition of this recent patent grant and the notice of allowance further strengthen our intellectual property position and highlight our commitment to innovation in advancing the surgical treatment of bunion patients,” said John T. Treace, CEO of Treace Medical.

Treace actively protects its innovations through patenting and is gratified that the United States Patent and Trademark Office and patent agencies worldwide continue to recognize the novelty of Treace’s contributions to the field. The Company has a global portfolio of over 35 granted patents and 60 pending patent applications, including over 30 pending US patent applications. Additional details on Treace’s patent coverage can be found at www.treace.com/patents.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot which could provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.